FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 253 filers reported holding FATE THERAPEUTICS INC in Q1 2022. The put-call ratio across all filers is 0.41 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $212 | -55.5% | 100 | 0.0% | 0.00% | – |
| Q2 2023 | $476 | -16.5% | 100 | 0.0% | 0.00% | – |
| Q1 2023 | $570 | -43.5% | 100 | 0.0% | 0.00% | – |
| Q4 2022 | $1,009 | -90.8% | 100 | -78.7% | 0.00% | -100.0% |
| Q3 2022 | $11,000 | -8.3% | 470 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $12,000 | -33.3% | 470 | 0.0% | 0.00% | 0.0% |
| Q1 2022 | $18,000 | -33.3% | 470 | 0.0% | 0.00% | -50.0% |
| Q4 2021 | $27,000 | -3.6% | 470 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $28,000 | -31.7% | 470 | 0.0% | 0.00% | -33.3% |
| Q2 2021 | $41,000 | +5.1% | 470 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $39,000 | -25.0% | 470 | -17.5% | 0.00% | -25.0% |
| Q4 2020 | $52,000 | +333.3% | 570 | +83.9% | 0.00% | +300.0% |
| Q3 2020 | $12,000 | +9.1% | 310 | 0.0% | 0.00% | 0.0% |
| Q2 2020 | $11,000 | +57.1% | 310 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $7,000 | – | 310 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $7,163,616 | 2.64% |
| Redmile Group, LLC | 13,124,427 | $27,823,785 | 1.32% |
| Monaco Asset Management SAM | 1,847,944 | $3,917,641 | 1.16% |
| Casdin Capital, LLC | 2,050,000 | $4,346,000 | 0.48% |
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $1,484,000 | 0.21% |
| GCM Grosvenor Holdings, LLC | 495,916 | $1,051,342 | 0.21% |
| Nebula Research & Development LLC | 163,617 | $346,868 | 0.18% |
| Bellevue Group AG | 4,851,579 | $10,285,347 | 0.17% |
| Bruce & Co., Inc. | 200,000 | $424,000 | 0.14% |
| XTX Topco Ltd | 192,920 | $408,990 | 0.07% |